CBD is readily obtainable in most parts of the United States, though its exact legal status is in flux. All 50 states have laws legalizing CBD with varying degrees of restriction, and while the federal government still considers CBD in the same class as marijuana, it doesn’t habitually enforce against it. In December 2015, the FDA eased the regulatory requirements to allow researchers to conduct CBD trials. Currently, many people obtain CBD online without a medical cannabis license. The government’s position on CBD is confusing, and depends in part on whether the CBD comes from hemp or marijuana. The legality of CBD is expected to change, as there is currently bipartisan consensus in Congress to make the hemp crop legal which would, for all intents and purposes, make CBD difficult to prohibit.
CBD has been touted for a wide variety of health issues, but the strongest scientific evidence is for its effectiveness in treating some of the cruelest childhood epilepsy syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome (LGS), which typically don’t respond to antiseizure medications. In numerous studies, CBD was able to reduce the number of seizures, and, in some cases, it was able to stop them altogether. Videos of the effects of CBD on these children and their seizures are readily available on the Internet for viewing, and they are quite striking. Recently the FDA approved the first ever cannabis-derived medicine for these conditions, Epidiolex, which contains CBD.
Is cannabidiol legal?
CBD is commonly used to address anxiety, and for patients who suffer through the misery of insomnia, studies suggest that CBD may help with both falling asleep and staying asleep.
Side effects of CBD include nausea, fatigue and irritability. CBD can increase the level in your blood of the blood thinner coumadin, and it can raise levels of certain other medications in your blood by the exact same mechanism that grapefruit juice does. A significant safety concern with CBD is that it is primarily marketed and sold as a supplement, not a medication. Currently, the FDA does not regulate the safety and purity of dietary supplements. So, you cannot know for sure that the product you buy has active ingredients at the dose listed on the label. In addition, the product may contain other (unknown) elements. We also don’t know the most effective therapeutic dose of CBD for any particular medical condition.
CBD may offer an option for treating different types of chronic pain. A study from the European Journal of Pain showed, using an animal model, CBD applied on the skin could help lower pain and inflammation due to arthritis. Another study demonstrated the mechanism by which CBD inhibits inflammatory and neuropathic pain, two of the most difficult types of chronic pain to treat. More study in humans is needed in this area to substantiate the claims of CBD proponents about pain control.
Various studies have suggested the use of cannabinoids as possible treatments for inflammatory diseases in the airways, such as chronic obstructive pulmonary disease (COPD) [7,8]. The phytocannabinoids Δ 9 -THC , cannabidiol (CBD)  and cannabigerol (CBG)  are of particular interest due to their important effects on inflammation and the immune system, including inhibiting the activation of pro-inflammatory cells and the synthesis of pro-inflammatory mediators or reducing intracellular and mitochondrial oxidative stress . Additionally, it has been reported that CBD exhibits apoptotic properties in immune cell populations, leading to cannabinoid-induced immunosuppression . CBD and CBG alone, and in combination, have demonstrated apoptotic effects in tumour cells, in addition to their off-target effects essential for effective palliative care such as increased appetite, analgesic and anxiolytic properties . On the other hand, CBD  and CBG  have been demonstrated to exhibit anti-apoptotic properties in healthy cells under oxidative and inflammatory conditions. The anti-apoptotic effects of cannabinoids are mainly associated with cytokine modulation and antioxidant activity via downregulation of nitric oxide production .
Our results have extended the observations that CBD and CBG can demonstrate a clear anti-inflammatory effect in the lung by reducing the ability of LPS to induce neutrophil infiltration. However, more importantly, we have shown the relevance of determining the most appropriate formulation for any drug, as notwithstanding how effective an agent is in vitro, ultimately there is a need to deliver a sufficient amount of drug safely in an in vivo setting, and many factors other than the drug itself
Exposure to LPS (100 μg/ml; 20 min) resulted in a significant increase in total leukocytes in BAL fluid obtained 4 h ±30 min post-exposure (saline: 101 ± 7 × 10 4 vs LPS: 348 ± 115 × 10 4 leukocytes/ml, P < 0.001; Fig. 1 A; n = 4 for each group). A differential count of the leukocyte cells in the BAL indicated that neutrophils accounted for this increase in cell numbers (saline: 7 ± 7 × 10 4 vs LPS: 277 ± 83 × 10 4 neutrophils/ml (P < 0.0001, n = 4 per group) and represented 97 ± 7% of the total
The discovery of the endocannabinoid system (ECS) has enabled the growth of scientific evidence supporting the use of cannabis and cannabinoids as therapeutic agents for various diseases. The ECS is a complex lipid cell-signalling system comprised of: the cannabinoid receptors (CBRs; CB1 and CB2); the endogenous cannabinoids (endocannabinoids, ECs), anandamide (N-arachidonoylethanolamide, AEA) and 2-arachidonoylglycerol (2-AG); the AEA transporter protein (TP) and the enzymes responsible for the synthesis and degradation of endocannabinoids (fatty acid amide hydrolase, FAAH, or monoacylglycerol lipase, MGL) .
Challenge of animals  and people  with bacterial lipopolysaccharide (LPS) has been extensively used as a model to mimic the neutrophilia characterising COPD and to investigate the actions of novel anti-inflammatory drugs in development for the treatment of this disease . Therefore, we have investigated the effects of highly purified CBD and CBG administered alone or in combination for their impact on LPS-induced neutrophilia.
In research published in Free Radical Biology and Medicine, scientists at the University of Mississippi medical center described not only the complexities and challenges posed by trying to specifically target oxidative stress in a variety of disease states, but also the potential benefits of using CBD to accomplish this goal.
In the conclusion of the research publication, the authors stated:
Further, many of the health-related issues associated with obesity are a consequence of increased inflammation. CBD is being explored extensively in relation to obesity in hopes of reducing some of these important health consequences.
I have written extensively about how reducing dietary sugar and carbohydrates, while at the same time increasing dietary consumption of good fats along with dietary fiber, goes a long way towards reducing inflammation. Emerging research now demonstrates that cannabidiol (CBD) has significant potential in terms of limiting inflammation and downstream effects in terms of free radicals as well.
CBD, for example, has been demonstrated to be specifically effective in dealing with various types of pain. This activity is also thought to represent a manifestation of CBD working as an anti-inflammatory much as over the counter anti-inflammatory medications are used for typical aches and pains.